Commercial COVID-19 Oral Antivirals Memo
This memo provides an update on the status of the transition of Paxlovid and Lagevrio to the commercial market, highlighting the overlap of USG-distributed and commercial products. Information on processing claims for these medications are provided as is a figure that depicts primary Medicare beneficiary coverage pathways for commercial anti-virals for COVID-19.
Favorite:
Login to rate, favorite, and comments
on the article
Comments
0
Toggle Open/Close
You must Login to add a comment
- This item doesn't have any comments